Medigus (TLV:MDGS) late last week priced a $1.6 million direct placement and released its third quarter earnings, seeing operating losses drop compared with the same period during the previous year. In its direct placement, the company said it is offering 810,000 American depository shares at approximately $2 per ADS alongside unregistered warrants to purchase an additional […]
Medigus prices $7.5m round
Medigus (TLV:MDGS) today priced an upcoming offering, looking to raise approximately $7.5 million. The Israeli company plans to float approximately 979,714 Class A units in the offering at $3.50 per unit, and 1.2 million Class B units at $3.50 per unit. Each Class A unit in the round consists of 1 American Depositary Share and 1 Series […]
Medigus wins nod to start Chinese trial for Muse transoral stapler
Medigus (TLV:MDGS) said today it won approval from the China Food and Drug Administration to initiate a clinical study of its Muse endoscopic device designed for trans oral fundoplication procedures to treat gastroesophageal reflux disease. The Chinese Muse trial is slated to enroll 62 patients at across 5 centers in China, including The General Hospital of […]
Medigus raises $3m, partners with NASA
Medigus (TLV:MDGS) raised $3m in a closed equity financing round, according to an SEC filing from the endosurgical and imaging device company. The company also partnered with NASA, providing micro ScoutCams for its Robotic Refueling Mission. The Omer, Israel-based company develops minimally invasive endoscopic devices and procedures, including its Muse system for treating gastroesophageal reflux […]
EndoChoice prices $96m IPO at low end of range
EndoChoice yesterday priced its initial public offering at $15 per share, the low end of the range, raising $95.2 million for its Fuse full-spectrum endoscope. EndoChoice shares are due to begin trading on the New York Stock Exchange under the “GI” symbol today, the company said. Alpharetta, Ga.-based EndoChoice had said it planned to float 6.25 million shares […]
Medigus secures $5.6M in funding, reveals positive outcomes from study of its MUSE surgical endostapling device | Medtech funding for the week of September 15, 2014
Medigus raises $5.6M, touts clinical results for acid reflux device
September 12, 2014 by Arezu Sarvestani
Medigus raises $5.6M, touts clinical results for acid reflux device
Ex-Neuronetics, Abiomed exec is Intact Vascular’s new CEO | Personnel Moves
Intact Vascular said yesterday that it named medical device veteran Bruce Shook as its new president & CEO.
Acid reflux: Medigus raises $11M from U.S. and Israeli groups
Israel’s Medigus lands FDA win for new MUSE acid reflux treatment
Israel’s Medigus raises another $7M in support of acid reflux treatment
Israel-based Medigus closed a $7 million funding round, raised through sales of shares and options at about 20¢ apiece (NIS 0.72).
The sale, joined by investors in the U.S. as well as Israel, represents about 21% of the company’s voting power combined with about 17.3 million 3-year options, according to a press release.
MassDevice Network
@MassDevice
LinkedIn
YouTube